 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
40 News |  |
| 1234» |
- Observational data, Retrospective data, Journal, Real-world evidence, Adherence, Real-world: A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States. (Pubmed Central) - Sep 25, 2024
The findings of this study indicate that prucalopride has higher treatment persistence and adherence compared with other CIC prescription medications. This research represents the first instance of a real-world claims study showcasing such outcomes.
- What Happens in Vagus: A Case Series of Three Pain-Predominant DGBI Managed With Transauricular Vagal Nerve Stimulation (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_4577;
Adjunct pharmacological neuromodulators like nortriptyline, duloxetine and gabapentin were not helpful...We share our stimulation parameters and outcomes (Table 1) in management of three pain-predominant DGBIs, including functional dyspepsia, centrally mediated abdominal pain syndrome, and pain-predominant IBS-C. Figure: Table 1: taVNS in DGBI - Parameters of Stimulation and Outcomes
- Trulance (plecanatide) / Bausch Health
Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) and Bloating: Evaluation Using Trisymptom Composite Endpoints (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2863;
Plecanatide and placebo baseline mean symptom scores were 6.2 and 6.4 for abdominal pain and 6.4 and 6.6 for bloating, respectively, and both groups had a mean of 0.2 CSBMs/wk. The majority (71.7%) of patients had moderate/severe bloating.
- Linzess (linaclotide) / Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Amitiza (lubiprostone) / Takeda, Mallinckrodt
Hormone Replacement Therapy Is Associated With Increased Risk of Developing Irritable Bowel Syndrome in Post-Menopausal Women (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2857;
Post-propensity matching, each cohort comprised 46,627 patients. Among post-menopausal women prescribed HRT, 992 developed IBS at least 30 days after being prescribed HRT compared to 581 not prescribed HRT (OR=1.75, 95% CI [1.58-1.94]).
- Trulance (plecanatide) / Bausch Health
An Association Between IBS Quality of Life Score and Symptoms of Abdominal Pain, Bloating, and Cramping in IBS-C: A Pooled Phase 3 Trial Correlation Analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2855;
41; Figure ). In addition, a correlation between treatment satisfaction and each of the 3 IBS-C symptoms (abdominal pain, bloating, cramping) was observed over the 12-week treatment period ( r ?
- Single-Center Experience with Concomitant Use of Novel and Off-Label Prescriptions for Chronic Constipation (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2849;
The most common diagnoses supporting these prescriptions are listed in Table 1. 110 patients (79.7%) were prescribed monotherapy, 23 (16.67%) given dual therapy simultaneously, 4 (2.8%) given three agents simultaneously, and only 1 (0.7%) given four agents simultaneously.
- Trulance (plecanatide) / Bausch Health
Efficacy and Safety of Plecanatide in Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1127;
4349 participants received plecanatide, while 1967 received placebo. Decrease in abdominal pain in patients with IBS-C was significantly associated with the use of plecanatide (MD = -0.44, 95% CI -0.60; -0.27, P < 0.01).
- || Review, Journal: Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States. (Pubmed Central) - Aug 8, 2024
These agents are generally well tolerated and efficacious in improving IBS-C symptoms, including constipation and abdominal pain. In patients with persistent abdominal pain and/or psychological symptoms, brain-gut behavioral therapy or neuromodulator therapy may be beneficial.
- Trulance (plecanatide) / Bausch Health
EFFICACY AND SAFETY OF PLECANATIDE IN CHINESE PATIENTS WITH FUNCTIONAL CONSTIPATION: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL (Lehar 2) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2570;
Plecanatide had a significant efficacy for the treatment of Chinese FC patients, with a low rate of AEs and no systemic absorption. Plecanatide will be a good option in the management of Chinese FC patients.
- ||||||| Trulance (plecanatide) / Bausch Health
Trial completion, Trial completion date, Trial primary completion date: Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation (clinicaltrials.gov) - Jul 11, 2024
P3, N=648, Completed, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Plecanatide will be a good option in the management of Chinese FC patients. Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023
- || Review, Journal: Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome. (Pubmed Central) - Jun 10, 2024
Current clinical trials of new therapeutic options are not too successful and it seems that one of the plausible treatment options could be the multi-drug cocktail with some, or perhaps even all its ingredients emerging from drug re-purposing. Another important path that needs to be explored further in IBS-C patients is the adjustment of dietary habits and/or introduction of dietary or nutritional intervention.
- | Trulance (plecanatide) / Bausch Health
Journal: TNF-? can promote membrane invasion by activating the MAPK/MMP9 signaling pathway through autocrine in bone-invasive pituitary adenoma. (Pubmed Central) - May 13, 2024
SPD304 significantly inhibits the effect of TNF-? and may be applied in the clinical treatment of bone-invasive pituitary adenoma.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Treatment patterns, barriers, and associated costs reported by patients with chronic idiopathic constipation in the United States: Analysis from a cross-sectional observational study () - Apr 9, 2024 - Abstract #AMCP2024AMCP_140;
The high- est out-of-pocket costs for patients were related to seeing an HCP and those associated with OTC and prescription medications. These factors may affect patient access to therapies for CIC.
- IMPLICATIONS OF POPULAR TRENDING ANTI-OBESITY MEDICATIONS - AN INCREASE IN HEALTHCARE COST AND UTILIZATION FOR THE POPULATION WITH CONSTIPATION (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6908;
These factors may affect patient access to therapies for CIC. Inclusion criteria included obese patients started on an AOM (per the 2022 AGA Guideline on the Pharmacological Interventions for Adults with Obesity
- RISK OF CONSTIPATION WITH ANTI-OBESITY MEDICATION AND CURRENT PRESCRIBING PATTERN LANDSCAPE IN MANAGING THE SIDE EFFECT (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1364;
Black patients had higher rate of new constipation diagnosis and treatment compared to White patients. Semaglutide had the least risk for requiring constipation medication.
- ||||| Trulance (plecanatide) / Bausch Health
Enrollment closed: Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation (clinicaltrials.gov) - Jan 5, 2024
P3, N=640, Active, not recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Semaglutide had the least risk for requiring constipation medication. Recruiting --> Active, not recruiting
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Preclinical, Journal: The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics. (Pubmed Central) - Nov 30, 2023
These altered properties are reflected in the high concentrations of ligands required to elicit signaling responses in the mouse gut in preclinical models and the specificity of a guanylyl cyclase inhibitor towards human GC-C. Therefore, our studies identify considerations in using the murine model to test molecules for therapeutic purposes that work as either agonists or antagonists of GC-C, and vaccines for the bacterial heat-stable enterotoxin that causes watery diarrhea in humans.
- | Trulance (plecanatide) / Bausch Health
Retrospective data, Journal: Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. (Pubmed Central) - Oct 22, 2023
Therefore, our studies identify considerations in using the murine model to test molecules for therapeutic purposes that work as either agonists or antagonists of GC-C, and vaccines for the bacterial heat-stable enterotoxin that causes watery diarrhea in humans. Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS-C.
- ||| Trulance (plecanatide) / Bausch Health
P3 data, Journal: Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials. (Pubmed Central) - Aug 31, 2023
Diarrhea, the most common adverse event, occurred in 4.3% (3 mg), 4.0% (6 mg) and 1.0% (placebo) of patients, leading to study discontinuation in 1.2%, 1.4%, and 0 patients, respectively. Plecanatide is safe and effective for treating global and individual IBS-C symptoms.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Sudden Onset Persistent Colonic Hypomotility After Laparoscopic Sleeve Gastrectomy (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3857;
Bariatric patients with colonic motility dysfunction after LSG should be identified and their pathophysiology should be further explored in order to limit procedure complications, reduce health care costs, and improve quality of life. Figure: Image 1: CT Showing Recurrent Significant Right-Sided Colonic Stool Burden
- Prevalence and Choice of Pharmacologic Management of Functional Dyspepsia and Irritable Bowel Syndrome During Pregnancy (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2425;
17,984 of 48,208 IBSFD patients (37%) were exposed to proton pump inhibitors compared to 266,835 of 3,046,065 (9%) of NONE (OR 6.20; 95% CI 6.08 - 6.52). 1.4% of IBSFD were exposed to Rifaximin compared to 0.032% of NONE (OR 44.44; CI 40.19 - 49.14).
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Clinical: 9/My Practice🧑🏻⚕️@ebgidoc 💎Assess for pelvic floor dysfunction and consider anorectal manometry/defecography 💎Gauge expectations with your patients 💎Inquire about Tx💊that failed 💎Choose an affordable Tx💊 💎Start linaclotide/plecanatide if👤failed PEG or other💊 (Twitter) - Jul 12, 2023
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Clinical: 6/Results📊 Part 1: 🟢PEG🟰superior to placebo and strongly recommended for CIC 🟢Linaclotide, plecanatide & prucalopride🟰superior to placebo and strongly recommended AFTER OTC Tx failure👎🏻 *💪🏻=low/very low, 💪🏻💪🏻=moderate, 💪🏻💪🏻💪🏻=strong (Twitter) - Jul 12, 2023
- |||| Retrospective data, Review: 4/Design✏️ 💎Systematic review with meta-analysis assessing: 💊 🔸Fiber 🔸Osmotic laxatives: PEG, MgOx, lactulose 🔸Stimulant laxatives: bisacoyl, NaPicosulfate, senna 🔸Secretagogues: lubiprostone, linaclotide, plecanatide 🔸Serotonin type-4 agonist: prucalopride (Twitter) - Jul 12, 2023
- ||| Clinical guideline, Journal: American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. (Pubmed Central) - Jun 2, 2023
The guidelines are meant to provide a framework for approaching the management of CIC; clinical providers should engage in shared decision making based on patient preferences as well as medication cost and availability. Limitations and gaps in the evidence are highlighted to help guide future research opportunities and enhance the care of patients with chronic constipation.
- | Journal: Vibrant - an oral vibrating capsule for chronic idiopathic constipation. (Pubmed Central) - May 12, 2023
Limitations and gaps in the evidence are highlighted to help guide future research opportunities and enhance the care of patients with chronic constipation. No abstract available
- || Trulance (plecanatide) / Bausch Health
Clinical data, Journal: Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide. (Pubmed Central) - May 10, 2023
No abstract available Pooled data from identically designed CIC trials strengthened the ability to identify meaningful subgroup comparisons regarding plecanatide efficacy and safety.
- Trulance (plecanatide) / Bausch Health
PLECANATIDE IMPROVES ABDOMINAL PAIN, BLOATING, AND STRAINING SYMPTOMS IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A NEW COMPOSITE ENDPOINT ANALYSIS OF TWO RANDOMIZED, PHASE 3 TRIALS (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6643;
Pooled data from identically designed CIC trials strengthened the ability to identify meaningful subgroup comparisons regarding plecanatide efficacy and safety. Plecanatide treatment significantly improved multiple, concurrent, sensory-related symptoms (pain/bloating/straining) in adults with IBS-C.
- || Trulance (plecanatide) / Bausch Health
Trial completion date, Trial primary completion date: Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - Feb 8, 2023
P2, N=210, Recruiting, Sponsor: Bausch Health Americas, Inc.
Plecanatide treatment significantly improved multiple, concurrent, sensory-related symptoms (pain/bloating/straining) in adults with IBS-C. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || Review, Journal: Management of Opioid-induced Constipation in Older Adults. (Pubmed Central) - Dec 13, 2022
Because of the complex nature of absorption, distribution, metabolism, and excretion in the aging population, all agents used to treat OIC must be evaluated individually and reevaluated as patients continue to age. This review will serve as a guide to managing OIC in older adults.
- | Journal: Pharmacotherapeutic advances for chronic idiopathic constipation in adults. (Pubmed Central) - Nov 22, 2022
In addition, relamorelin, a ghrelin agonist, seems promising for accelerating colonic transit...On the other hand, the experience with these new agents is still limited, especially for long-term treatment. Another important point is that these new treatments for chronic idiopathic constipation are not available worldwide and their use could be somewhat limited by their still relatively high cost.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Enrollment open, Trial initiation date: GCC Agonist Signal in the Small Intestine (clinicaltrials.gov) - Oct 28, 2022
P1, N=43, Recruiting, Sponsor: National Cancer Institute (NCI)
Another important point is that these new treatments for chronic idiopathic constipation are not available worldwide and their use could be somewhat limited by their still relatively high cost. Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Oct 2022
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Trial initiation date: GCC Agonist Signal in the Small Intestine (clinicaltrials.gov) - Sep 29, 2022
P1, N=43, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Oct 2022 Initiation date: Oct 2022 --> Mar 2023
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Review, Journal: Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. (Pubmed Central) - Sep 20, 2022
Further, it is universally expressed in advanced metastatic colorectal tumors, as well as other cancer types that arise through intestinal metaplasia. In this context, GUCY2C satisfies many characteristics of a compelling target and biomarker for gastrointestinal malignancies.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Yes! The secretagogues, linaclotide (Linzess) and plecanatide (Trulance), are the only treatments receiving a strong recommendation based on high quality evidence in the ACG IBS guideline. (Twitter) - Sep 13, 2022
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Clinical, Patient reported outcomes: ⚠️Caution⚠️ ❗️Patient reported outcomes (PRO) is 💜 by FDA, but hard to define ❗️Cannot translate findings over to Plecanatide, another secretagogue. ❗️only 4.6% of pt on linaclotide had diarrhea and 1.6% of patients discontinued 💊 due to diarrhea, which is ⬇️ than prior RCTs (Twitter) - Sep 7, 2022
- Trulance (plecanatide) / Bausch Health
Plecanatide Improves Symptoms of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome With Constipation (IBS-C) Across Age Subgroups: An Analysis of Four Phase 3 Trials (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_2481;
P3
6%) were ≥ 60 y. For CIC, significantly more plecanatide-treated patients were durable overall CSBM responders vs placebo in all 3 age subgroups ( Figure ). For IBS-C, significantly more plecanatide-treated patients were overall responders vs placebo in the < 40 y and 40-59 y subgroups, whereas a numeric difference favoring plecanatide was observed for the ≥ 60 y subgroup ( Table ).
- Trulance (plecanatide) / Bausch Health
Plecanatide Improves Severe Abdominal Pain and Severe Bloating in Individuals With Irritable Bowel Syndrome With Constipation (IBS-C): A Pooled Analysis of Two Phase 3 Trials (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_2480;
P3
A significantly greater percentage of plecanatide-treated patients with severe baseline abdominal pain were responders vs placebo at Week 12 (Δ=14.6%, P =0.01 [ Figure ]). In addition, a significantly greater percentage of plecanatide-treated patients with severe baseline bloating treated were responders vs placebo at Week 12 (Δ=14.9%; P =0.005 [ Figure ]).
- ||| Clinical guideline: AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. (Pubmed Central) - Jun 30, 2022
The panel made a strong recommendation for linaclotide (high certainty) and conditional recommendations for tenapanor, plecanatide, tegaserod, and lubiprostone (moderate certainty), polyethylene glycol laxatives, tricyclic antidepressants, and antispasmodics (low certainty). The panel made a conditional recommendation against the use of selective serotonin reuptake inhibitors (low certainty).
- | Ibsrela (tenapanor) / Ardelyx, Kyowa Kirin, Knight Therap
Journal: Tenapanor (Ibsrela) for irritable bowel syndrome with constipation. (Pubmed Central) - Jun 8, 2022
The panel made a conditional recommendation against the use of selective serotonin reuptake inhibitors (low certainty). No abstract available
- | Trulance (plecanatide) / Bausch Health
Journal: Liquid-Phase Total Synthesis of Plecanatide Aided by Diphenylphosphinyloxyl Diphenyl Ketone (DDK) Derivatives. (Pubmed Central) - May 31, 2022
Herein we developed diphenylphosphinyloxyl diphenyl ketone (DDK) derivatives as greener supports with unique precipitation-inducing properties to aid the liquid-phase total synthesis of plecanatide without the use of chromatography. Plecanatide could be obtained in high yield, and the ultimately sheared DDK derivative residue could be directly recycled or regenerated for reuse.
- |||||| Trulance (plecanatide) / Bausch Health
Enrollment open, Trial initiation date: Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation (clinicaltrials.gov) - May 18, 2022
P3, N=640, Recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Plecanatide could be obtained in high yield, and the ultimately sheared DDK derivative residue could be directly recycled or regenerated for reuse. Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Mar 2022
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Journal: GUCY2C-Enriched Intestinal Neuropod Cells Modulate Visceral Pain. (Pubmed Central) - May 14, 2022
They support a model in which GUCA2B sufficiency activates GUCY2C to suppress DRG neuron excitability, while GUCA2B insufficiency silences GUCY2C to produce DRG hyperexcitability and CVP. Finally, they suggest that linaclotide relieves CVP by stimulating GUCY2C neuropod cells to inhibit DRG excitability and nociceptive signaling.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Trial completion date, Trial initiation date, Trial primary completion date: GCC Agonist Signal in the Small Intestine (clinicaltrials.gov) - May 12, 2022
P1, N=39, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Finally, they suggest that linaclotide relieves CVP by stimulating GUCY2C neuropod cells to inhibit DRG excitability and nociceptive signaling. Trial completion date: Sep 2024 --> Feb 2025 | Initiation date: Apr 2022 --> Aug 2022 | Trial primary completion date: Sep 2024 --> Feb 2025
- Trulance (plecanatide) / Bausch Health
PLECANATIDE PRODUCES A MORE RAPID AND SUSTAINED CLINICAL RESPONSE COMPARED TO PLACEBO IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_6177;
P3
More plecanatide-treated patients achieved sustained responses (≥9/12 weeks) for bowel movement, pain, and bloating compared to placebo. Plecanatide was more likely to be associated with a sustained effect than placebo.
- A REAL-WORLD STUDY OF PERSISTENCE AND ADHERENCE TO PRESCRIPTION MEDICATIONS IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_5932;
Conclusion sAlmost half of patients receiving a prescription CIC medication did not refill it. This study showed higher persistence and adherence to prucalopride versus other prescription treatments, which could inform real-world therapy decisions and improve healthcare outcomes.
- ||| Trulance (plecanatide) / Bausch Health
P3 data, Journal: The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials. (Pubmed Central) - Apr 21, 2022
P3
Plecanatide treatment is safe and efficacious for patients with CIC when administered with concomitant acid suppression medication. ClinicalTrials.gov identifiers: NCT02122471 and NCT01982240.
- | Journal, HEOR, Real-world evidence: Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. (Pubmed Central) - Apr 7, 2022
Given the broad spectrum of available agents, therapy should be tailored by mutual decision-making between the patient and practitioner. Overall, patients need to be actively monitored and managed to maximize clinical outcomes.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Journal: Guanylin and uroguanylin: a promising nexus in intestinal electrolyte and fluid homeostasis. (Pubmed Central) - Feb 22, 2022
Moreover, GC-C/cGMP signaling is involved in the regulation of intestinal barrier integrity, epithelial cell renewal, cell cycle, DNA damage repair, inflammatory responses, epithelial-mesenchymal transition and cancer progression. Impairment of GC-C activation causes functional gastrointestinal disorders, inflammatory bowel disease, visceral pain and colorectal cancer, suggesting that oral supplementation of guanyl peptide analogs (linaclotide, plecanatide) may prove useful for the treatment of these diseases.
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Journal: Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. (Pubmed Central) - Feb 15, 2022
We performed a narrative review of the literature to summarize these important determinants of treatment choice including: labeled indications; clinical profiles of efficacy, safety, and tolerability of prescription drugs; and cost-effectiveness for diarrhea-predominant IBS drugs (IBS-D: alosetron, eluxadoline, and rifaximin) and constipation-predominant IBS drugs (IBS-C: linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor). We then review the standard model of shared decision-making aimed at guiding an informed, patient-centered discussion to integrate comparative clinical and cost outcomes toward choosing an IBS treatment in practice.